General MM

EHA 2019 | Mechanisms of resistance to IMiDs in MM


At the 24th Congress of the European Hematology Association (EHA), Enrique Ocio from the Marqués de Valdecilla University Hospital, Santander, ES, talks about mechanisms of resistance to immunomodulatory drugs (IMiDs) in multiple myeloma (MM).
Enrique Ocio discusses the involvement of cereblon in resistance to IMiDs, concluding that whilst it is an important in some patients, it is not the only factor. Using combination approaches may, in future, avoid the development of resistance, though it is important that we have alternative approaches to treat resistant patients.